Goldsmith Named CEO of CancerCare
PATRICIA GOLDSMITH was named CEO of CancerCare.
Goldsmith previously served as executive vice president and chief operating officer at the National Comprehensive Cancer Network, where she was responsible for overall operations and provided oversight for national programs and initiatives. She will take the job May 5.
Prior to joining NCCN, she was vice president for institutional development and public affairs and marketing at the H. Lee Moffitt Cancer Center & Research Institute.
BECKY DEKAY was named president of the Association of Community Cancer Centers at its annual meeting April 2. She is director of oncology services at the Feist-Weiller Cancer Center at LSU Health Shreveport.
DeKay has been active in ACCC since joining the staff of LSU Health Shreveport in 2003. She has served on the governmental affairs committee, chaired both the membership and the strategic planning committees, and has published articles in the association’s journal. More recently, she served as ACCC treasurer for two years.
BERT HOWARD O’NEIL was named the inaugural Joseph W. and Jackie J. Cusick Professor of Oncology and a professor of medicine at the Indiana University School of Medicine. He is also the phase I director and director of the gastrointestinal cancer research program at the IU Simon Cancer Center, and he will represent the cancer center on the Big Ten Cancer Research Consortium steering committee.
O’Neil was most recently an associate professor of medicine and director of the gastrointestinal malignancies research program at the University of North Carolina at Chapel Hill. He also was the medical director of the UNC Lineberger Comprehensive Cancer Center’s clinical protocol office. His area of expertise is in gastrointestinal cancers, with a concentration on pancreas, colorectal, and hepatocellular carcinomas.
The professorship was established by Jackie Cusick in memory of her husband Joseph, who co-founded, co-owned and co-operated NCA Group. He was instrumental in building New Hope Presbyterian Church in Fishers, Ind. It is the intent of the donor that the holder be involved in clinical or basic science research aimed at enhancing treatment for patients with gastrointestinal cancers.
MD ANDERSON CANCER CENTER formed a research alliance with GlaxoSmithKline to strengthen its efforts in advancing anticancer immunotherapies.
This marks the fourth and final collaboration in a plan to partner with pharmaceutical companies as part of MD Anderson’s Moon Shots Program. GSK and MD Anderson will work to identify therapeutic approaches, evaluate patient responses in clinical trials, and develop immunotherapy drugs.
THE AMERICAN ASSOCIATION FOR CANCER RESEARCH is now accepting applications for the Stand Up To Cancer-Cancer Research U.K. Translational Research Fellowship, which will provide up to four grants for postdoctoral or clinical research fellows, each up to $315,000, over a four-year period.
This grant opportunity is provided by SU2C and Cancer Research U.K. and is the first joint research project resulting from the collaboration between the two groups announced in 2012.
The fellowship will provide four years of research support to early-career investigators in the U.S. and U.K. Research projects must be translational in nature and address critical problems in cancer with the potential to deliver benefit to patients.
The proposed work must be performed in two phases, one in the U.S. and one in the U.K. Each phase must be one to three years in length, and the total support period for this fellowship is a maximum of four years.
Project proposals are due by noon ET July 28, via proposalCENTRAL.
For general information on eligibility criteria, the application process, and other details about this grant, visit the AACR website.